CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The Repro-TIL project focuses on improving immunotherapy for solid tumors by developing a platform to selectively expand tumor-reactive T cells. It aims to enhance the effectiveness of adoptive cell transfer therapies, particularly for melanoma and other difficult-to-treat cancers.
Solid tumors present a significant challenge in oncology due to the limited efficacy of current therapies and resistance to immunotherapies like checkpoint inhibitors.
While adoptive cell transfer (ACT) using Tumor-Infiltrating Lymphocytes (TIL) has shown promise in immunogenic tumors like melanoma, broader success has been hindered by inefficient TIL expansion, T-cell exhaustion, and low tumor reactivity (<0.5% tumor-reactive clones in TIL products).
These limitations result in inconsistent out…
ASGARD THERAPEUTICS AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, Lund
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Denmark, Hillerod
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
